deFilippi Christopher, Wasserman Steven, Rosanio Salvatore, Tiblier Eric, Sperger Heidi, Tocchi Monica, Christenson Robert, Uretsky Barry, Smiley Mathew, Gold Judith, Muniz Henry, Badalamenti John, Herzog Charles, Henrich William
Department of Medicine, University of Maryland School of Medicine, Baltimore 21201, USA.
JAMA. 2003 Jul 16;290(3):353-9. doi: 10.1001/jama.290.3.353.
Cardiac troponin T (cTnT) and C-reactive protein (CRP) are prognostic markers in acute coronary syndromes. However, for patients with end-stage renal disease (ESRD) the ability of combinations of these markers to predict outcomes, and their association with cardiac pathology, are unclear.
To investigate the association between levels of cTnT and CRP and long-term risk of cardiac pathology and death in patients with ESRD.
DESIGN, SETTING, AND PARTICIPANTS: A prospective cohort study initiated February through June 1998 and enrolling 224 patients with ESRD from 5 hemodialysis centers in the Houston-Galveston region of Texas. Levels of cTnT and CRP were analyzed at study entry in patients without ischemic symptoms.
All-cause mortality during a mean follow-up of 827 (range, 29-1327) days. Secondary outcomes in predefined substudies were coronary artery disease (CAD), decreased (< or =40%) left ventricular ejection fraction (LVEF), and presence of left ventricular hypertrophy (LVH).
One hundred seventeen (52%) patients died during follow-up. For levels of cTnT and CRP, progressively higher levels predicted increased risk of death compared with the lowest quartile (for cTnT quartile 2: unadjusted hazard ratio [HR], 2.2; 95% confidence interval [CI], 1.2-4.1; quartile 3: HR, 2.7; 95% CI, 1.5-4.9; quartile 4: HR, 3.0; 95% CI, 1.6-5.3. For CRP quartile 2: HR, 0.9; 95% CI, 0.5-1.6; quartile 3: HR, 1.8; 95% CI, 1.1-3.1; quartile 4: HR, 1.8; 95% CI, 1.1-3.2). Both cTnT and CRP remained independent predictors of death after adjusting for a number of potential confounders. The combination of cTnT and CRP results provided prognostic information when patients were divided into groups at or above and below the biomarker medians (high cTnT/high CRP levels vs low cTnT/low CRP levels for risk of death: HR, 2.5; 95% CI, 1.5-4.0). Elevated levels of cTnT, but not CRP, were strongly associated with diffuse CAD (n = 67; 0%, 25%, 50%, and 62% prevalence of multivessel CAD across progressive cTnT quartiles, P<.001). An LVEF of 40% or less was identified in 4 (9%), 3 (8%), 10 (27%), and 7 (19%) of patients across cTnT quartiles (P =.07). No trend for cTnT levels was found among patients with LVH (P =.45); similarly, no trend for CRP was found among patients with LVH (P =.65) or an LVEF of 40% or less (P =.75).
Among stable patients with ESRD, increasing levels of cTnT and CRP are associated with increased risk of death. Furthermore, higher levels of cTnT may identify patients with severe angiographic coronary disease.
心肌肌钙蛋白T(cTnT)和C反应蛋白(CRP)是急性冠状动脉综合征的预后标志物。然而,对于终末期肾病(ESRD)患者,这些标志物组合预测预后的能力及其与心脏病理的关联尚不清楚。
研究ESRD患者中cTnT和CRP水平与心脏病理及死亡长期风险之间的关联。
设计、地点和参与者:一项前瞻性队列研究,于1998年2月至6月启动,纳入了得克萨斯州休斯顿-加尔维斯顿地区5个血液透析中心的224例ESRD患者。对无缺血症状患者在研究入组时分析cTnT和CRP水平。
平均随访827天(范围29 - 1327天)期间的全因死亡率。预定义亚研究中的次要结局为冠状动脉疾病(CAD)、左心室射血分数降低(LVEF)(≤40%)和左心室肥厚(LVH)。
随访期间117例(52%)患者死亡。对于cTnT和CRP水平,与最低四分位数相比,水平逐渐升高预示死亡风险增加(对于cTnT四分位数2:未调整风险比[HR],2.2;95%置信区间[CI],1.2 - 4.1;四分位数3:HR,2.7;95% CI,1.5 - 4.9;四分位数4:HR,3.0;95% CI,1.6 - 5.3。对于CRP四分位数2:HR,0.9;95% CI,0.5 - 1.6;四分位数3:HR,1.8;95% CI,1.1 - 3.1;四分位数4:HR,1.8;95% CI,1.1 - 3.2)。在调整了多个潜在混杂因素后,cTnT和CRP仍然是死亡的独立预测因素。当根据生物标志物中位数将患者分为高于或低于中位数两组时,cTnT和CRP结果的组合提供了预后信息(高cTnT/高CRP水平与低cTnT/低CRP水平相比,死亡风险:HR,2.5;95% CI,1.5 - 4.0)。cTnT水平升高,但CRP水平不升高,与弥漫性CAD密切相关(n = 67;在cTnT四分位数逐渐升高过程中,多支血管CAD的患病率分别为0%、25%、50%和62%,P<0.001)。在cTnT各四分位数的患者中,分别有4例(9%)、3例(8%)、10例(27%)和7例(19%)患者的LVEF≤40%(P = 0.07)。在LVH患者中未发现cTnT水平的变化趋势(P = 0.45);同样,在LVH患者或LVEF≤40%的患者中也未发现CRP水平的变化趋势(P = 0.65和P = 0.75)。
在稳定的ESRD患者中,cTnT和CRP水平升高与死亡风险增加相关。此外,较高的cTnT水平可能识别出患有严重冠状动脉造影疾病的患者。